We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
We need to prioritise areas of guidance development and delivery that will have the greatest impact on the health and care system. To do this we're developing a new centralised approach.
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update) Draft guidance consultation NICE guideline 24 February 2025 ...
Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
All NICE products on COVID-19. Includes any guidance and advice.
All NICE products on vulnerable groups. Includes any guidance and quality standards.
We make 4 types of recommendation which apply across all our guidance products. These allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice. We ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果